• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rechallenging to Hydroxycarbamide Post Thalidomide Treatment and Response in a Non Transfusion-Dependent Patient, is it Possible?

作者信息

Ricchi Paolo, Costantini Silvia, Spasiano Anna, Cinque Patrizia, Di Matola Tiziana, Ammirabile Massimiliano, Filosa Aldo

机构信息

1UOSD Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale "A.Cardarelli", Via A.Cardarelli 9, 80131 Naples, Italy.

UOC Biochimica Clinica, AORN Ospedali dei Colli, PO Monaldi, Naples, Italy.

出版信息

Indian J Hematol Blood Transfus. 2019 Jul;35(3):587-589. doi: 10.1007/s12288-019-01093-x. Epub 2019 Feb 11.

DOI:10.1007/s12288-019-01093-x
PMID:31388283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6646488/
Abstract
摘要

相似文献

1
Rechallenging to Hydroxycarbamide Post Thalidomide Treatment and Response in a Non Transfusion-Dependent Patient, is it Possible?沙利度胺治疗后对非输血依赖型患者再次使用羟基脲及其反应，这可行吗？
Indian J Hematol Blood Transfus. 2019 Jul;35(3):587-589. doi: 10.1007/s12288-019-01093-x. Epub 2019 Feb 11.
2
Thalidomide has a significant effect in patients with thalassemia intermedia.沙利度胺对中间型地中海贫血患者有显著疗效。
Hematology. 2018 Jan;23(1):50-54. doi: 10.1080/10245332.2017.1354427. Epub 2017 Jul 18.
3
The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.低剂量沙利度胺在一名不可输血的非输血依赖型地中海贫血患者中的长期广泛疗效。
Blood Cells Mol Dis. 2016 Mar;57:97-9. doi: 10.1016/j.bcmd.2016.01.003. Epub 2016 Jan 16.
4
Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case.羟基脲长期治疗继发的黑甲症：一例原发性血小板增多症病例
Case Rep Hematol. 2015;2015:653178. doi: 10.1155/2015/653178. Epub 2015 Aug 2.
5
[Advances in thalidomide therapy for idiopathic myelofibrosis].沙利度胺治疗原发性骨髓纤维化的研究进展
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):651-3.
6
Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide.沙利度胺治疗慢性输血依赖型胃窦血管扩张症（西瓜胃）
Eur J Gastroenterol Hepatol. 2006 Apr;18(4):455-6. doi: 10.1097/00042737-200604000-00024.
7
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.沙利度胺治疗低危骨髓增生异常综合征患者的非随机剂量递增II期研究：法国骨髓增生异常研究组的Thal-SMD-2000试验
Br J Haematol. 2005 Dec;131(5):609-18. doi: 10.1111/j.1365-2141.2005.05817.x.
8
Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.羟基脲（羟基脲）用于输血依赖型β地中海贫血。
Cochrane Database Syst Rev. 2019 Mar 16;3(3):CD012064. doi: 10.1002/14651858.CD012064.pub2.
9
[Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].来那度胺治疗原发性骨髓纤维化患者实现输血独立
Rinsho Ketsueki. 2018;59(3):323-325. doi: 10.11406/rinketsu.59.323.
10
Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.羟基脲改变镰状细胞贫血患儿的红细胞基因表达。
Br J Haematol. 2012 Apr;157(2):240-8. doi: 10.1111/j.1365-2141.2012.09061.x. Epub 2012 Feb 24.

引用本文的文献

1
Investigating the Efficacy and Safety of Thalidomide for Treating Patients With -Thalassemia: A Meta-Analysis.沙利度胺治疗β地中海贫血患者的疗效与安全性研究：一项荟萃分析
Front Pharmacol. 2022 Jan 11;12:814302. doi: 10.3389/fphar.2021.814302. eCollection 2021.

本文引用的文献

1
Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.可溶性转铁蛋白受体-1水平与非输血依赖型地中海贫血患者的首次诊断年龄、治疗干预风险及铁过载相关。
Ann Hematol. 2017 Sep;96(9):1541-1546. doi: 10.1007/s00277-017-3057-z. Epub 2017 Jul 14.
2
Soluble form of transferrin receptor as a biomarker of overall morbidity in patients with non-transfusion-dependent thalassaemia: a cross-sectional study.可溶性转铁蛋白受体作为非输血依赖型地中海贫血患者总体发病率的生物标志物：一项横断面研究
Blood Transfus. 2016 Nov;14(6):538-540. doi: 10.2450/2016.0279-15. Epub 2016 May 3.
3
The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.低剂量沙利度胺在一名不可输血的非输血依赖型地中海贫血患者中的长期广泛疗效。
Blood Cells Mol Dis. 2016 Mar;57:97-9. doi: 10.1016/j.bcmd.2016.01.003. Epub 2016 Jan 16.
4
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.β地中海贫血：科学发现与创新疗法开发的典型疾病。
Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827.
5
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.既往或同时 IFN 治疗对去铁酮诱导的粒细胞缺乏和中性粒细胞减少的影响：一项回顾性研究。
Expert Opin Drug Saf. 2010 Nov;9(6):875-81. doi: 10.1517/14740338.2010.510831.
6
Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.羟基脲治疗中间型地中海贫血：长期随访中部分患者疗效降低
Br J Haematol. 2006 Apr;133(1):105-6. doi: 10.1111/j.1365-2141.2006.06002.x.
7
Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation.干细胞因子（c-kit配体）影响过敏性气道炎症中的嗜酸性粒细胞募集和组胺水平。
J Immunol. 1996 May 15;156(10):3945-51.